Trial reportTrials2026
A study of self-management interventions for neurogenic bladder patients based on symptom management theory.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the clinical efficacy of a self‑management intervention programme based on symptom management theory for patients with neurogenic bladder (NB).
methodsOne hundred NB patients treated at a rehabilitation centre between May 2023 and May 2025 who met the inclusion criteria were randomly assigned to two groups (n = 50 each). The control group received routine nursing care, while the observation group received the theory‑based self‑management intervention. Outcomes included self‑management capability, quality of life, voiding parameters (bladder capacity, residual urine volume, daily voiding frequency), NB symptoms, anxiety/depression, and neurogenic bowel function.
resultsAfter 4 weeks, the observation group showed higher self‑management scores and bladder capacity than the control group [57 (49,66) vs. 35 (28,42) points; (376.18 ± 59.65) vs. (224.38 ± 38.13) mL], and lower quality‑of‑life scores, residual urine volume, and daily voiding frequency [(15.10 ± 5.12) vs. (22.02 ± 5.64) points; (103.56 ± 24.25) vs. (155.18 ± 57.43) mL; (9.72 ± 2.33) vs. (17.52 ± 2.87) times; all P < 0.05]. Symptom scores (NBSS, NBDS, SAS, SDS) were also lower in the observation group (P < 0.05).
conclusionThe programme enhances self‑management, improves bladder function, alleviates symptoms, and increases quality of life in NB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.